Optimization of therapy of cerebrovascular disorders (CVD) is one of the most critical health problems. The current treatment regimen of CVD turns out to be often insufficient. Search for new drugs with cerebroprotective and antihypoxic properties is an essential task of modern medicine and pharmacy. Attention to cytokine mechanisms of ischemic brain damage in clinics and experimental research has been increased recently. Interleukin-1 (IL-1) receptor blockade is a perspective way of cerebroprotection that requires a more profound study of its mechanisms. The article contains the results of a study of cerebroprotective and antihypoxic properties of the recombinant IL-1 antagonist raleukin on a model of bilateral carotid occlusion in rats. Recombinant receptor antagonist IL-1 raleukin (15 mg/kg) did not affect basal blood flow in the internal carotid artery of intact group animals. Still, it prevented its decrease approximately three times in case of occlusion of both common carotid arteries followed by reperfusion. Indicators of the cerebroprotective effect of studied medication were reducing the acidotic blood shift flowing from the brain of animals with irreversible bilateral carotid occlusion, neuronal degradation, and weakening.
- Keywords
- Cerebral ischemia, bilateral carotid occlusion, interleukin-1, neuron-specific enolase, raleukin,
- MeSH
- Interleukin-1 metabolism pharmacology MeSH
- Cardiovascular Diseases * MeSH
- Rats MeSH
- Brain * blood supply metabolism MeSH
- Receptors, Interleukin-1 metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Interleukin-1 MeSH
- Receptors, Interleukin-1 MeSH
